Search
Ocriplasmin
go.drugbank.com/drugs/DB08888ApprovedWithdrawnOcriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012. … Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system.
Tirbanibulin
go.drugbank.com/drugs/DB06137ApprovedInvestigational[A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri. … Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin.
Efgartigimod alfa
go.drugbank.com/drugs/DB15270ApprovedInvestigationalEfgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis. … [L43190] A formulation for subcutaneous use that combines efgartigimod alfa and hyaluronidase was later approved for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP
Xenon-133
go.drugbank.com/drugs/DB09315ApprovedXenon-133 is an inhaled radionuclide used for lung imaging, imaging blood flow in the brain, and to assess pulmonary function.
Tideglusib
go.drugbank.com/drugs/DB12129ApprovedInvestigationalWithdrawnTideglusib is under the investigation for the development of treatments for Alzheimer's disease and for progressive supranuclear palsy. … It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3).
Eluxadoline
go.drugbank.com/drugs/DB09272ApprovedInvestigationalof abdominal pain and reductions in the Bristol Stool Scale. … Agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromePyruvate dehydrogenase E1 component subunit alpha, testis-specific form, mitochondrial
go.drugbank.com/bio_entities/BE0000609TargetHumansTogether with PDHB forms the heterotetrameric E1 subunit of the pyruvate dehydrogenase (PDH) complex in testis (PubMed:14638692).
Polypeptides: Pyruvate dehydrogenase E1 component subunit alpha, testis-specific form, mitochondrialZongertinib
go.drugbank.com/drugs/DB18762ApprovedInvestigational[L53873,A274363] On August 8, 2025, the US FDA granted accelerated approval to zongertinib for the treatment of advanced forms of non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain … [L53873,A274363] It covalently binds to the HER2 receptor, including exon 20 insertions, and inhibits downstream signaling pathways while sparing wild-type epidermal growth factor receptor (EGFR), which
Relugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigational[A225926] In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and [norethindrone] under the market name Myfembree for the first once-daily treatment for the management … [L27996] In addition to its relative ease-of-use, relugolix was shown to be superior in the depression of testosterone levels when compared to [leuprolide], another androgen deprivation therapy used in
Equine Botulinum Neurotoxin B Immune FAB2
go.drugbank.com/drugs/DB13903ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes B in adults and pediatric patients. … Equine Botulinum Neurotoxin B Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype B.